Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) EBT: 2020-2025

Historic EBT for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Sep 2025 value amounting to -$45.1 million.

  • Maravai Lifesciences Holdings' EBT rose 73.77% to -$45.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$218.0 million, marking a year-over-year decrease of 149.47%. This contributed to the annual value of -$261.5 million for FY2024, which is 142.33% down from last year.
  • Maravai Lifesciences Holdings' EBT amounted to -$45.1 million in Q3 2025, which was up 39.09% from -$74.1 million recorded in Q2 2025.
  • Maravai Lifesciences Holdings' 5-year EBT high stood at $656.2 million for Q4 2023, and its period low was -$172.1 million during Q3 2024.
  • For the 3-year period, Maravai Lifesciences Holdings' EBT averaged around $16.8 million, with its median value being -$22.4 million (2024).
  • In the last 5 years, Maravai Lifesciences Holdings' EBT soared by 21,448.45% in 2021 and then plummeted by 737.15% in 2024.
  • Maravai Lifesciences Holdings' EBT (Quarterly) stood at $144.7 million in 2021, then tumbled by 33.74% to $95.9 million in 2022, then spiked by 584.41% to $656.2 million in 2023, then tumbled by 107.02% to -$46.1 million in 2024, then soared by 73.77% to -$45.1 million in 2025.
  • Its EBT was -$45.1 million in Q3 2025, compared to -$74.1 million in Q2 2025 and -$52.7 million in Q1 2025.